Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1293309 | 1.00 | LPL (0.32) | LPLLIPG | |
| SCHEMBL31478095 | 0.78 | LPL (0.38) | LPLLIPG | |
| SCHEMBL23980720 | 0.76 | LPL (0.36) | LPLLIPG | |
| SCHEMBL29947404 | 0.76 | LPL (0.36) | LPLLIPG | |
| SCHEMBL28839065 | 0.71 | F2 (0.31) | LPLLIPG | |
| SCHEMBL26120079 | 0.71 | GPR35 (0.35) | LPLLIPG | |
| SCHEMBL27179975 | 0.70 | TPMT (0.36) | LPLLIPG | |
| SCHEMBL3477926 | 0.69 | CXCR2 (0.31) | — | |
| SCHEMBL1293013 | 0.68 | JAK2 (0.35) | LPLLIPG | |
| SCHEMBL1293011 | 0.68 | JAK2 (0.35) | LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2563785-A1 | COMPOUNDS AS AGONISTS OF S1P1 RECEPTORS | Glaxo Group Limited (GB) | 2013-03-06 | — | — | EP | disclosed |
| US-8389508-B2 | Heterocyclic compounds | GLAXO GROUP LIMITED (GB) | 2013-03-05 | — | — | US | disclosed |
| WO-2011134280-A1 | COMPOUNDS AS AGONISTS OF S1P1 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2011-11-03 | — | — | WO | disclosed |
| US-20110269738-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269738-A1 | COMPOUNDS | CYP11B2, CYP11B1, GPR119 | LPL 142/4885LIPG 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.